OT | p-value | ||
---|---|---|---|
Malea | Femaleb | ||
Age | |||
N | 10 | 17 | p = 0.841a |
Mean ± SD [95% CI] | 26.6 ± 8.7 [20.4; 32.8] | 26.1 ± 5.3 [23.6; 28.5] | |
Min–max | 16–48 | 17–35 | |
Median | 25 | 27 | |
Percentiles (25th; 75th) | 21; 29 | 21; 29 | |
Days after treatment start | |||
N | 10 | 17 | p = 0.083b |
Mean ± SD | 13 ± 2 | 14 ± 2 | |
Min–max | 10–15 | 11–17 | |
Median [95% CI]d | 14 [12; 14] | 14 [14; 16] | |
Percentiles (25th; 75th) | 12; 14 | 13; 16 | |
PY (µg/l) | |||
N | 10 | 17 | p = 0.537b |
Mean ± SD | 1527 ± 667 | 1550 ± 1411 | |
Min–max | 789–2630 | 29–6160 | |
Median [95% CI]d | 1321 [962; 2140] | 1230 [780; 1890] | |
Percentiles (25th; 75th) | 962; 2140 | 780; 1980 | |
SA [mg/l)c | |||
N | 10 | 17 | p = 0.386b |
Mean ± SD | 82.4 ± 47.9 | 69.1 ± 44.2 | |
Min–max | 9.0–159.0 | 9.0–166.0 | |
Median [95% CI]d | 82.4 [53.5; 115.0] | 70.4 [52.4; 89] | |
Percentiles (25th; 75th) | 53.5; 115 | 52.4; 89.0 |